decapeptide
/ C4X Discovery
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
December 20, 2023
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
(clinicaltrials.gov)
- P2 | N=84 | Active, not recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Apr 2027 ➔ Aug 2026
Trial completion date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PIK3CA
August 03, 2021
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
(clinicaltrials.gov)
- P2; N=84; Active, not recruiting; Sponsor: Washington University School of Medicine; Recruiting ➔ Active, not recruiting
Enrollment closed • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • PIK3CA
May 06, 2019
PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
(clinicaltrials.gov)
- P2; N=87; Recruiting; Sponsor: Washington University School of Medicine; Trial completion date: Apr 2025 ➔ Apr 2027; Trial primary completion date: Dec 2020 ➔ Apr 2022
Clinical • Combination therapy • Trial completion date • Trial primary completion date
1 to 3
Of
3
Go to page
1